THE DEAL, AT A GLANCE
From the announcementTriveni Bio
01What happenedTriveni Bio raised $65M Series C, announced 2026-06-17From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Why it mattersTriveni Bio's $65M Series C is positioned to extend the clinical scope of TRIV-573 and support next-stage company growth in healthcare and life sciences.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Triveni Bio · Financing Record
Explore source-linked visual explanations for Triveni Bio. Unsupported claims are withheld while source review continues.
Record 6168 · Recorded date: 2026-06-17
Explore company records →